Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 vs Pembrolizumab in PD-L1+ Advanced NSCLC
NCT05499390Phase 3Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Nov 2022
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ivonescimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2022; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05499390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05499390.